CClinicalTrials.gg
RecruitingNCT07044726Updated May 4, 2026

Betadine vs Sterile Water for Periurethral Preparation

A Phase 4 interventional study of Povidone-Iodine and Sterile water in Catherization and Urinary Tract Infection Bacterial, sponsored by University of Louisville. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Louisville · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 3 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water (water that has been treated to remove bacteria and living organisms) vs Betadine also known as Povidone-Iodine (a medical grade cleaning solution) changes the rates of bacteria in the urine after a temporary catheter, or draining tube, is placed into the bladder. Chemical antiseptics, including Betadine, are the current standard of care. An additional goal of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water vs betadine changes the amount of discomfort or pain patients experience with placement of a temporary catheter, or draining tube, in the bladder.

02

Conditions studied

  • Catherization
  • Urinary Tract Infection Bacterial

Keywords

  • Betadine
  • Sterile Water
  • Catherization
03

In context

Lead sponsor

University of Louisville is the lead sponsor of 284 studies on the registry; 53 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged 18+
  • Patient undergoing in office straight catherization

Exclusion criteria

Exclusion Criteria:

  • History of culture proven recurrent urinary tract infection (2 in any 6-month period or 3 in any 12-month period)
  • Urine Analysis with +Nitrites
  • Catherization for any reason in the last 4 weeks
  • History of Iodine allergy
  • Patients unable to speak English
  • Patient does not have the capacity to consent
  • 2-3rd trimester pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
148 participants (estimated)

Study arms

  • Active comparator
    Betadine

    Betadine periurethral preparation

    Drug: Povidone-Iodine

  • Sham comparator
    Sterile Water

    Sterile Water periurethral preparation

    Drug: Sterile water

Interventions

  • DrugPovidone-Iodine

    Providone-Iodine for periurethral preparation

  • DrugSterile water

    Sterile water for periurethral preparation

06

What researchers measure

Primary outcomes

  1. Bacteruria

    Bacteruria defined as the presence of bacteria within patient urine evaluated with urinalysis. Bacterial presence will be further characterized by colony forming unit count on urine culture.

    Time frame: Within 2 weeks of the patients procedure date

Secondary outcomes

  1. Urethral Pain

    Urethral pain at the time of catheterization rated by patients on a visual analog scale zero to ten with zero representing no pain and ten representing the worst pain of their life.

    Time frame: At the time of catherization

07

Study locations

2 of 2 sites recruiting
  • UofL Physicians - Urogynecology Springs Urogynecology Office
    Louisville, Kentucky 40205, United States
    Recruiting
  • UofL Health - Urogynecology Mary & Elizabeth Hospital, Medical Plaza 3
    Louisville, Kentucky 40215, United States
    Recruiting
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 10, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Individual participant data collected in this study will be used solely for the purposes of completing this study

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044726
Lead sponsor
University of Louisville
Responsible party
Ankita Gupta (Associate Fellowship Director of Urogynecology and Pelvic Reconstructive Surgery, University of Louisville) — Principal investigator
First posted
Jul 1, 2025
Start date
Jun 30, 2025
Primary completion
May 21, 2028 (estimated)
Completion
May 21, 2028 (estimated)
Last update
May 4, 2026

Study contacts

Kathryn C Seymour, MD
Contact
kathryn.seymour@louisville.edu
502-588-7660
Ankita Gupta, MD, MPH
Contact
502-588-7660
Ankita Gupta, MD, MPH
principal investigator · University of Louisville

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion